Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

NCT07708194 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer
Hormone Receptor-Positive Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: entinostat
DRUG: Pyrotinib
DRUG: endocrine therapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]